Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

France: These 2 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "France: These 2 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can WINLEVI (clascoterone) generic drug versions launch in France?

Generic name: clascoterone
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: August 03, 2027
Generic Entry Controlled by: France Patent 25C1053

Drug Price Trends for WINLEVI
WINLEVI is a drug marketed by Sun Pharm. There are seven patents protecting this drug. There has been litigation on patents covering WINLEVI

See drug price trends for WINLEVI.

The generic ingredient in WINLEVI is clascoterone. Additional details are available on the clascoterone profile page.

# France Branded and Generic Drug Markets: Regulatory Opportunities, Pricing, Patent Risk and Market Access

Last updated: October 12, 2026

France is a large, state-regulated pharmaceutical market with strong demand for innovative medicines, extensive public reimbursement, and policy pressure to expand generic and biosimilar use. Market access depends on European marketing authorization, French health-technology assessment, reimbursement approval, and price negotiation with the Economic Committee for Health Products, or CEPS.

Branded manufacturers benefit from rapid access to hospital products, high-value specialty medicines, and public incentives for industrial investment. Generic companies benefit from a large reimbursed market and automatic substitution rules, but face aggressive price reductions, reference pricing, supply obligations, pharmacy discount limits, and political pressure to localize production.

The main commercial risks are low net prices, lengthy reimbursement negotiations, mandatory price cuts after generic entry, procurement concentration, manufacturing shortages, and increasing scrutiny of promotional and supply practices.

What is the structure of the French branded drug market?

France has a predominantly public reimbursement system. The statutory health insurance system, Assurance Maladie, funds most prescription medicines through reimbursement rates determined by the medicine’s medical benefit and the severity of the treated condition.

France divides medicines into several reimbursement categories:

Category Typical reimbursement position Commercial significance
Major or serious conditions Often 65% or higher, with some products reimbursed at 100% Supports broad outpatient uptake
Moderate-benefit medicines Often 30% Greater patient co-payment and price sensitivity
Low-benefit medicines Often 15% Weak reimbursement economics
Hospital-only medicines Hospital budgets, listed products, or special funding mechanisms Access depends heavily on hospital procurement
Nonreimbursed products Patient or private-insurance payment Limited volume unless strong consumer demand

The French market combines outpatient reimbursement with hospital purchasing. Hospital products may receive separate financing through the “liste en sus,” which allows certain high-cost medicines to be funded outside the standard hospital tariff. Inclusion on this list can materially improve uptake for oncology, immunology, rare disease, and advanced therapy products.

For branded medicines, the key commercial variables are:

  1. The European regulatory pathway.
  2. The Haute Autorité de Santé, or HAS, assessment.
  3. The reimbursement rate.
  4. The CEPS price negotiation.
  5. Hospital listing and procurement.
  6. Generic or biosimilar competition.
  7. Supply and manufacturing commitments.

France is also an important launch market for advanced therapies and hospital medicines because the government has used early-access and innovation pathways to provide coverage before ordinary reimbursement decisions are complete.

How does FDA-equivalent regulation work in France?

France does not have a standalone national equivalent to the U.S. Food and Drug Administration for most prescription medicines. Regulatory authorization is mainly handled through the European Medicines Agency, national competent authorities, or mutual-recognition procedures.

European and French regulatory routes

The principal routes are:

  • Centralized European authorization through the European Commission following an EMA opinion.
  • National authorization by the French National Agency for the Safety of Medicines and Health Products, or ANSM.
  • Decentralized and mutual-recognition procedures for products outside the mandatory centralized scope.
  • French authorization of manufacturing, distribution, pharmacovigilance, and controlled-substance activities through ANSM and related authorities.

The centralized route is mandatory for many biotechnology products, advanced therapies, orphan medicines, and certain oncology, HIV, diabetes, neurodegenerative, and autoimmune products. National procedures remain relevant for many conventional generics and products outside mandatory centralized categories.

A European marketing authorization does not automatically produce French reimbursement or commercial access. The sponsor must complete the French health-technology assessment and pricing process.

What is the French reimbursement and pricing process?

HAS evaluates a new medicine through the Transparency Commission. Its conclusions generally include:

  • Service médical rendu, or SMR, which assesses the medical service provided.
  • Amélioration du service médical rendu, or ASMR, which assesses improvement over existing treatment.
  • The target population.
  • The place in the treatment strategy.
  • Comparative clinical value and therapeutic alternatives.

ASMR is particularly important for pricing. A high ASMR rating can support a premium price, while an ASMR rating of V indicates no demonstrated improvement and typically creates strong pricing pressure.

CEPS negotiates the price for reimbursed medicines. The negotiation considers:

  • HAS clinical benefit and added benefit.
  • Prices in other European countries.
  • Budget impact.
  • Expected patient population.
  • Existing therapeutic alternatives.
  • Industrial and supply commitments.
  • Confidential rebates and managed-entry arrangements.

The French market uses several access mechanisms before or alongside ordinary reimbursement:

Mechanism Regulatory or commercial role
Early access, “accès précoce” Temporary coverage for eligible serious conditions before ordinary reimbursement
Compassionate access, “accès compassionnel” Access for individual patients or defined populations when no suitable authorized option exists
Post-authorization reimbursement Standard route after HAS and CEPS review
Hospital “liste en sus” Separate funding for qualifying high-cost hospital medicines
Temporary authorization or named-patient mechanisms Narrow access for products under specific conditions

Early access can accelerate revenue generation, but it requires evidence commitments, data collection, and later transition into the standard reimbursement system. The government may also apply financial clawbacks or price reconciliation mechanisms.

When do branded drugs lose exclusivity in France?

France follows European and international intellectual-property rules. The practical loss of exclusivity depends on several rights rather than a single expiry date.

Protection Typical term or effect
Basic patent Generally 20 years from filing
Supplementary Protection Certificate Up to five additional years, subject to EU conditions
Paediatric extension Six-month extension in qualifying cases
Orphan-medicine exclusivity Usually 10 years, potentially extended to 12 years for pediatric compliance
Data and market protection Commonly described as 8 years of data protection plus 2 years of market protection, with a possible additional year for a new indication
Formulation or process patent May extend protection beyond the compound patent if valid and enforceable
Method-of-use patent Can constrain labeled or patented indications, but enforcement against generic sales is fact-specific

The 8+2+1 regulatory exclusivity framework is distinct from patent protection. Generic applicants may rely on the originator’s dossier after the applicable data-protection period, subject to EU rules and patent certification requirements.

Patent expiry does not automatically produce immediate generic entry. Entry also depends on:

  • Marketing authorization approval.
  • Reimbursement registration.
  • Patent validity and litigation.
  • SPC status.
  • Manufacturing readiness.
  • Pharmacy substitution and wholesaler supply.
  • Any settlement or launch agreement.

What patents protect branded medicines in France?

A French or European patent estate may include:

  • Composition-of-matter patents.
  • Salt, polymorph, stereoisomer, or crystalline-form patents.
  • Formulation patents.
  • Dosage-regimen patents.
  • Method-of-use patents.
  • Combination-treatment patents.
  • Drug-device patents.
  • Manufacturing-process patents.
  • Intermediate or purification patents.

European patents validated in France are enforceable before French courts. The Unified Patent Court may also have jurisdiction over relevant European patents unless the patent holder has opted out, subject to the applicable transitional framework and patent status.

For high-value products, the strongest protection generally remains a valid composition-of-matter patent or SPC. Secondary patents can delay or complicate entry, but their commercial value depends on claim scope, infringement evidence, prosecution history, and the availability of noninfringing alternatives.

What formulation patents affect French generic entry?

Formulation patents can be commercially important for modified-release products, injectables, inhaled medicines, long-acting products, transdermal systems, and complex biologics.

A generic company may avoid a formulation patent by:

  • Using a different excipient system.
  • Adopting an alternative release mechanism.
  • Changing particle size or manufacturing parameters.
  • Launching a different dosage form.
  • Limiting the product label to nonpatented uses where legally permissible.

French market entry therefore requires a claim-by-claim freedom-to-operate analysis. An expired active-ingredient patent does not eliminate risk from a valid formulation, device, process, or use patent.

How large is the French generic drug market?

Generics are a central part of French medicines policy. The government has used substitution, prescribing targets, reference pricing, reimbursement rules, and pharmacy incentives to increase generic utilization.

France has historically had a lower generic penetration rate than some northern European markets, although uptake has increased through policy reforms and substitution incentives. Market share varies materially by molecule, therapeutic class, hospital versus retail channel, and the presence of biosimilar competition.

Key demand drivers include:

  • Pharmacist substitution.
  • Generic prescribing targets.
  • “Non-substitution” restrictions.
  • Reference pricing and capped reimbursement.
  • Physician and patient acceptance.
  • Shortages of originator and generic products.
  • Pharmacy margin structures.
  • Tendering and purchasing groups.

Generic substitution is not unconditional. Physicians can oppose substitution in defined clinical circumstances, and pharmacists must comply with applicable product, prescription, and supply rules. The government has also limited the use of “non-substitutable” designations to specific situations.

Generic companies face price compression after entry. France has repeatedly reduced prices for originator and generic medicines through statutory and negotiated measures. Market entry may increase unit volume while reducing gross margin.

What is the regulatory status of biosimilars in France?

Biosimilars are approved under EU procedures and must demonstrate high similarity to the reference biological medicine in quality, safety, and efficacy. EMA authorization is separate from French reimbursement and substitution policy.

France has supported biosimilar uptake through:

  • Hospital tenders.
  • Physician prescribing incentives.
  • National and regional guidance.
  • Reimbursement policies.
  • Substitution rules for selected biological products.

Automatic substitution for biosimilars has developed more slowly and with more conditions than generic substitution. French law permits pharmacist substitution in defined circumstances, but implementation depends on product categories, ministerial rules, prescriber information, and pharmacovigilance requirements.

The largest biosimilar opportunities are in:

  • Insulins.
  • Filgrastim and pegfilgrastim.
  • Erythropoietins.
  • Monoclonal antibodies.
  • Fertility medicines.
  • Hospital-administered biologics.

Biosimilar companies face a different risk profile from conventional generic companies. The principal barriers are clinical development cost, manufacturing capacity, interchangeability policy, hospital contracting, physician confidence, and reference-product patent settlements.

Which companies compete in the French branded and generic markets?

France has a mixed competitive structure.

Branded and innovative companies

Major participants include:

  • Sanofi.
  • Servier.
  • Pierre Fabre.
  • Ipsen.
  • Roche.
  • Novartis.
  • Pfizer.
  • AstraZeneca.
  • Merck & Co.
  • Bristol Myers Squibb.
  • Johnson & Johnson.
  • AbbVie.
  • Eli Lilly.
  • Novo Nordisk.
  • Gilead Sciences.

French companies have strong positions in vaccines, specialty medicines, oncology, rare disease, diabetes, immunology, and hospital products.

Generic and biosimilar companies

Important participants include:

  • Biogaran.
  • Sandoz.
  • Viatris.
  • Teva.
  • Fresenius Kabi.
  • Zentiva.
  • Arrow Génériques.
  • EG Labo.
  • Mylan-related and other established European supply platforms.
  • Hospital-focused biosimilar and injectable manufacturers.

Competition is not determined solely by authorization. Distribution reach, wholesaler relationships, shortage management, pharmacy service, tendering capability, and manufacturing location influence market share.

What licensing deals and industrial opportunities exist in France?

France offers opportunities for licensing and co-development in oncology, rare diseases, vaccines, cell and gene therapy, immunology, metabolic disease, and hospital injectables.

The principal deal structures include:

  • In-licensing of European or French commercialization rights.
  • Co-promotion with a French specialty company.
  • Contract manufacturing.
  • Technology transfer to a French site.
  • Distribution agreements.
  • Hospital tender partnerships.
  • Co-development of advanced therapies.
  • Licensing of biosimilar or complex-generic platforms.

Industrial policy is a major factor. France has sought to reduce dependence on overseas manufacturing for essential medicines and active pharmaceutical ingredients. Companies that establish or maintain French or European manufacturing capacity may receive stronger consideration in supply-security policy, procurement, and government negotiations.

The opportunities are strongest where a company can offer:

  • Reliable local supply.
  • Strategic stocks.
  • French or European manufacturing.
  • Shortage prevention.
  • Advanced-therapy expertise.
  • Specialized hospital distribution.
  • Evidence supporting comparative clinical value.

What litigation and settlement risks affect French drug entry?

France has an active patent litigation environment, but it differs from the U.S. Hatch-Waxman system. Generic and biosimilar companies may challenge European patents or SPCs through national proceedings, European Patent Office opposition, or Unified Patent Court litigation where applicable.

Common disputes involve:

  • SPC validity.
  • Inventive step.
  • Sufficiency and plausibility.
  • Claim construction.
  • Infringement by formulation or process.
  • Dosage-regimen claims.
  • Cross-border injunction exposure.
  • Preliminary injunctions.
  • Confidential settlements and launch dates.

Paragraph IV terminology is primarily associated with U.S. ANDA litigation. France does not use an identical Paragraph IV certification system. European generic applicants must still analyze patent barriers, provide appropriate patent declarations, and manage launch risk across France and other EU markets.

Settlement agreements may include:

  • An agreed launch date.
  • A royalty-bearing license.
  • Supply arrangements.
  • A nonassert covenant.
  • Restrictions on formulation or indication.
  • Confidential commercial terms.

Any settlement must be assessed under EU and national competition law. Agreements that delay generic or biosimilar entry can attract regulatory scrutiny.

What are the main regulatory challenges for companies entering France?

The largest barriers are commercial and administrative rather than authorization-related.

Pricing pressure

France applies sustained pressure to reduce medicine expenditure. A product with limited added clinical value may obtain reimbursement but face a price close to existing alternatives.

Lengthy market-access sequence

Authorization, HAS review, reimbursement approval, and CEPS negotiations operate as separate steps. A marketing authorization alone does not guarantee launch.

Evidence requirements

HAS increasingly focuses on comparative effectiveness, patient-relevant outcomes, real-world evidence, and budget impact. Weak comparative data can reduce ASMR and pricing leverage.

Supply obligations

Manufacturers must maintain continuity of supply and provide shortage information. Failure to meet obligations can damage commercial relationships and trigger regulatory action.

Hospital procurement

Hospital tenders can produce rapid volume shifts and substantial price reductions. Winning a tender may require supply reliability, local service, and competitive manufacturing economics.

Generic substitution and physician behavior

Substitution policy can increase generic utilization, but physician restrictions, patient resistance, and product shortages can limit the expected volume transfer.

Data and compliance controls

Companies must comply with French rules on promotional activities, transparency, pharmacovigilance, anti-gift restrictions, personal-data protection, and interactions with healthcare professionals.

How does France compare with other European drug markets?

Factor France Germany United Kingdom
Primary access model HAS assessment plus CEPS negotiation AMNOG assessment and negotiated price NICE or NHS England guidance, commercial and national arrangements
Generic policy Strong substitution and price controls High generic use with reference pricing and rebate tenders Strong generic use through NHS prescribing
Innovative-product access Early access and hospital mechanisms Rapid launch often followed by benefit assessment Health-technology assessment strongly affects NHS uptake
Pricing environment Generally aggressive Negotiated after comparative benefit assessment Variable by NHS pathway and confidential discounts
Hospital market Significant tendering and special funding Regional and hospital contracting NHS procurement and framework agreements
Manufacturing policy Strong focus on supply security and reindustrialization Strong industrial base Post-Brexit supply and regulatory considerations

France is attractive for high-need products and hospital innovation, but less attractive for products whose value proposition depends only on a modest price premium.

What generic launch scenarios exist in France?

A generic or biosimilar launch usually falls into one of four scenarios:

  1. Immediate launch after relevant patent and regulatory barriers expire.
  2. Launch after patent litigation or opposition proceedings.
  3. License-based launch under a settlement agreement.
  4. Delayed launch because of formulation, process, device, or manufacturing constraints.

The most important commercial variables are first-mover timing, pharmacy substitution, reimbursement registration, wholesaler inventory, and the number of approved competitors.

A crowded launch can reduce prices quickly. A first generic entrant may obtain volume advantages, but the advantage can disappear if several suppliers enter simultaneously or if the originator maintains a strong authorized-generic, branded-generic, or patient-support strategy.

Key Takeaways

  • France is a major reimbursed pharmaceutical market with separate regulatory, assessment, reimbursement, pricing, and procurement stages.
  • HAS determines medical and comparative value; CEPS negotiates reimbursed prices.
  • Early access can accelerate launch for high-need medicines but creates evidence and financial obligations.
  • Generic and biosimilar utilization is policy-supported, although substitution remains more conditional than in some other European markets.
  • Patent risk extends beyond active-ingredient expiry to SPCs, formulations, devices, manufacturing processes, and methods of use.
  • France offers commercial opportunities in specialty medicines, hospital products, advanced therapies, biosimilars, and supply-secure manufacturing.
  • The principal challenges are price compression, supply obligations, tendering, evidence requirements, and delayed reimbursement negotiations.
  • Market-entry planning should integrate patent clearance, HAS strategy, CEPS pricing, hospital procurement, pharmacy substitution, and supply-chain localization.

FAQs

Is France a good launch market for innovative medicines?

France is attractive for medicines addressing serious unmet needs, rare diseases, oncology, advanced therapies, and hospital conditions. Products with limited comparative benefit face greater pricing and reimbursement pressure.

Can French pharmacies automatically substitute a generic?

Pharmacist substitution is permitted under French rules but is subject to product eligibility, prescription requirements, medical exceptions, and applicable non-substitution provisions.

Does a European patent automatically protect a medicine in France?

A European patent must be validated or otherwise effective in France, and its enforceability depends on claim scope, validity, maintenance, and the relevant court or Unified Patent Court jurisdiction.

Are biosimilars automatically interchangeable with biologics in France?

Interchangeability and pharmacist substitution depend on French rules applicable to the product and treatment stage. Automatic substitution is more restricted and conditional than conventional generic substitution.

How can a company improve French reimbursement prospects?

The strongest levers are comparative clinical evidence, a clear unmet-need position, credible budget-impact analysis, supply commitments, early engagement with HAS, and a pricing strategy aligned with the product’s ASMR potential.

References

  1. European Medicines Agency. (n.d.). Generic and hybrid medicines. https://www.ema.europa.eu
  2. European Medicines Agency. (n.d.). Biosimilar medicines. https://www.ema.europa.eu
  3. European Commission. (n.d.). Pharmaceutical strategy for Europe. https://health.ec.europa.eu
  4. Haute Autorité de Santé. (n.d.). Medicinal products assessment and reimbursement. https://www.has-sante.fr
  5. Haute Autorité de Santé. (n.d.). Early access to medicinal products. https://www.has-sante.fr
  6. National Agency for the Safety of Medicines and Health Products. (n.d.). Medicinal products and regulatory procedures. https://ansm.sante.fr
  7. Organisation for Economic Co-operation and Development. (2023). Health at a glance 2023: OECD indicators. OECD Publishing. https://doi.org/10.1787/7a7afb35-en
  8. World Health Organization. (2022). Global benchmarking exercise on national regulatory systems. https://www.who.int
  9. French Ministry of Health and Prevention. (n.d.). Medicines policy and access to healthcare products. https://sante.gouv.fr
  10. European Patent Office. (n.d.). Unitary Patent and Unified Patent Court. https://www.epo.org

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.